Anti-Therapeutic Action: Ego dissolution

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

mycolabadmin

This review examines how psychedelic drugs like ketamine, MDMA, and psilocybin could offer new hope for people with PTSD by working on the brain differently than current medications. These compounds work quickly and help the brain form new neural connections that can help people process traumatic memories more effectively. When combined with therapy, these drugs show promise in reducing PTSD symptoms faster and more effectively than traditional antidepressants. The review also explains how doctors could use personalized medicine approaches using brain scans and genetic testing to determine which treatment would work best for each individual patient.

Read More »

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

mycolabadmin

Schizophrenia involves excessive loss of connections between brain cells in areas responsible for emotion and thinking, leading to negative symptoms and cognitive problems. Research shows that small doses of psychedelics like psilocybin can promote the growth of new brain connections and reduce inflammation. The authors suggest that microdosing psychedelics alongside standard treatments might help restore these lost connections and improve symptoms that don’t respond well to current medications.

Read More »

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework

mycolabadmin

Psychedelic drugs like LSD and psilocybin show promise in treating depression with effects lasting months after single doses. However, scientists debate whether the hallucinations and mystical experiences these drugs produce are necessary for their healing effects. This review proposes a framework to test whether lower doses without hallucinations might still provide antidepressant benefits, similar to how anesthesia-administered ketamine works without the patient’s awareness.

Read More »

Psychedelics action and schizophrenia

mycolabadmin

This review examines how psychedelic drugs like psilocybin and LSD affect the brain, particularly through serotonin receptors. While these compounds can produce psychosis-like symptoms similar to schizophrenia, they also promote brain plasticity and growth of neural connections. The article discusses whether psychedelics could potentially treat negative symptoms and cognitive problems in schizophrenia patients, despite their mind-altering properties, possibly through lower doses or non-hallucinogenic alternatives.

Read More »

Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey

mycolabadmin

This survey studied how autistic adults feel about using psychedelics like psilocybin mushrooms for mental health. Nearly 70% of participants had tried psychedelics before and most found them helpful for anxiety and depression. Many participants were interested in trying them or participating in research, though legal and practical barriers stood in the way. The study suggests that psychedelics could be a promising treatment option for autistic people with mental health challenges.

Read More »

Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology

mycolabadmin

Psilocybin, the active compound in magic mushrooms, shows promise for treating depression and other mental health conditions. This review examines how psilocybin works in the brain, particularly by affecting brain regions involved in self-reflection and emotion regulation. The authors argue that new brain recording techniques are needed to fully understand how psilocybin produces its beneficial effects, which could help improve treatments for people with severe depression.

Read More »
Scroll to Top